Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H27NO2.ClH |
Molecular Weight | 373.916 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3
InChI
InChIKey=VDPUXONTAVMIKZ-UHFFFAOYSA-N
InChI=1S/C22H27NO2.ClH/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);1H
Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21584062 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Survector Approved UseSurvector 100mg tablet is used in the treatment of depression. Launch Date1977 |
PubMed
Title | Date | PubMed |
---|---|---|
[Amineptin-induced hepatitis: differential diagnosis of biliary microlithiasis]. | 1982 Nov |
|
[Acneiform eruption induced by amineptin (Survector)]. | 1989 |
|
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case]. | 1991 Dec |
|
The serotonin syndrome. | 1992 Oct |
|
[Acne induced by amineptin: adnexal toxiderma]. | 1996 |
|
WHO Expert Committee on Drug Dependence. Thirty-second report. | 2001 |
|
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. | 2001 |
|
Acneiform eruption caused by amineptine. A case report and review of the literature. | 2001 Jul |
|
Social stress in anorexia nervosa: a review of immuno-endocrine relationships. | 2001 Jun |
|
Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. | 2001 Mar |
|
WHO Expert Committee on Drug Dependence. | 2003 |
|
Discriminating different classes of toxicants by transcript profiling. | 2004 Aug |
|
Sex-dependent modulation of treatment response. | 2004 Mar |
|
Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. | 2008 Sep |
|
Improving pain management communication: how patients understand the terms "opioid" and "narcotic". | 2008 Sep |
|
Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability. | 2009 |
|
Spectroscopic and electrochemical analysis of psychotropic drugs. | 2009 Jan |
|
Prevalence of antidepressants and biosimilars in elite sport. | 2009 Jun |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1797329
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
32499
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
250-107-3
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
DBSALT000803
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
SUB00447MIG
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
30272-08-3
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
A5P604A12R
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
m1673
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID20952633
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
100000085152
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
34869
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY | |||
|
50003
Created by
admin on Fri Dec 15 17:00:55 GMT 2023 , Edited by admin on Fri Dec 15 17:00:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD